TY - JOUR AU - Lim, Fang Qi AU - Chan, Allison Si-Yu AU - Yokomori, Rui AU - Huang, Xiao Zi AU - Theardy, Madelaine Skolastika AU - Yeoh, Allen Eng Juh AU - Tan, Shi Hao AU - Sanda, Takaomi PY - 2023/02/01 Y2 - 2024/03/28 TI - Targeting dual oncogenic machineries driven by TAL1 and PI3K-AKT pathways in T-cell acute lymphoblastic leukemia JF - Haematologica JA - haematol VL - 108 IS - 2 SE - Articles DO - 10.3324/haematol.2022.280761 UR - https://haematologica.org/article/view/haematol.2022.280761 SP - 367-381 AB - T-cell acute lymphoblastic leukemia (T-ALL) is a malignancy of thymic T-cell precursors. Overexpression of oncogenic transcription factor TAL1 is observed in 40-60% of human T-ALL cases, frequently together with activation of the NOTCH1 and PI3K-AKT pathways. In this study, we performed chemical screening to identify small molecules that can inhibit the enhancer activity driven by TAL1 using the GIMAP enhancer reporter system. Among approximately 3,000 compounds, PIK- 75, a known inhibitor of PI3K and CDK, was found to strongly inhibit the enhancer activity. Mechanistic analysis demonstrated that PIK-75 blocks transcriptional activity, which primarily affects TAL1 target genes as well as AKT activity. TAL1-positive, AKT-activated T-ALL cells were very sensitive to PIK-75, as evidenced by growth inhibition and apoptosis induction, while T-ALL cells that exhibited activation of the JAK-STAT pathway were insensitive to this drug. Together, our study demonstrates a strategy targeting two types of core machineries mediated by oncogenic transcription factors and signaling pathways in T-ALL. ER -